Product Images Aripiprazole

This is a chart illustrating the effects of various drugs on the pharmacokinetics of aripiprazole. The drugs mentioned include ketoconazole as a CYP3A4 inhibitor, quinidine as a CYP2D6 inhibitor, carbamazepine as a CYP3A4 inducer, famotidine as a gastric acid blocker, valproate, and lorazepam. The chart shows changes in Aripiprazole Fold Change and 90% CI compared to the reference (without interacting drug). It also includes values for AUC and Cmax.*

This text presents information on the effects of different drugs on the pharmacokinetics of dehydro-aripiprazole. It includes data on the fold change and 90% Confidence Intervals for this drug when combined with CYP3A4 Inhibitors (e.g., ketoconazole), CYP2D6 Inhibitors (e.g., quinidine), CYP3A4 Inducers (e.g., carbamazepine), Gastric Acid Blockers (e.g., famotidine), and other drugs like valproate and lorazepam. The text also mentions parameters such as Cmax and Tmax. This information is valuable for understanding how the metabolism of aripiprazole is affected when used concomitantly with these drugs.*

This is a description of the effects of aripiprazole on the pharmacokinetics of other drugs. The text mentions various drugs such as extropmethorphan, omeprazole, lamotrigine, valproate, lorazepam, and desmethylvenlafaxine, and their parameters like AUC and Cmax. It also discusses fold change and confidence intervals in comparison to reference values without interacting drugs.*

This is a table showing different factors affecting pharmacokinetics in special populations like gender, age, hepatic impairment, and renal impairment. It compares changes in these factors relative to normal references.*

This is a description of the effects of intrinsic factors on the pharmacokinetics of dehydro-aripiprazole. The data seems to show changes in pharmacokinetic parameters such as Cmax related to intrinsic factors like gender, age, hepatic impairment, and renal impairment. The figure displays the relative changes in these parameters compared to a reference value.*

This is a Kaplan-Meier estimation graph showing the cumulative proportion of patients with relapse in a schizophrenia study. The data compares patients on Aripiprazole and those on placebo over a period of days from randomization. The number of subjects at risk is displayed for each time point along with the proportion with relapse.*

This text provides information on a package of Abilify 20mg Tablet from Aurobindo Pharma USA, Inc. The package contains 30 tablets and lists storage instructions to keep the product at room temperature. The package also reminds to keep all drugs out of reach of children. The NDC number is 7133513641.*